






Bell , A. and Monaghan, P. and Page, A.P. (2006) Peptidyl-prolyl cis-
trans isomerases (immunophilins) and their roles in parasite 
biochemistry, host-parasite interaction and antiparasitic drug action. 







Deposited on: 25 February 2009 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 






Manuscript Number:  IJPara05_N06R2              
 
Title:  Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-
parasite interaction and antiparasitic drug action                           
 
Article Type:  Invited Review 
 
Section/Category:  Invited Review 
 
Keywords:  Protein folding; Cyclophilin; FKBP; Cyclosporin; FK506; Rapamycin. 
 
Corresponding Author:  Dr Angus Bell, PhD 
 
Corresponding Author's Institution:  University of Dublin - Trinity College 
 
First Author:  Angus Bell, PhD 
 
Order of Authors:  Angus Bell, PhD; Paul Monaghan, PhD; Antony P Page, PhD 
 
Manuscript Region of Origin: IRELAND 
 
Abstract:  Immunophilin is the collective name given to the cyclophilin and FK506-binding protein (FKBP) 
families.  As the name suggests, these include the major binding proteins of certain immunosuppressive 
drugs: cyclophilins for the cyclic peptide cyclosporin A and FKBPs for the macrolactones FK506 and 
rapamycin.  Both families, although dissimilar in sequence, possess peptidyl-prolyl cis-trans isomerase 
activity in vitro and can play roles in protein folding and transport, RNA splicing and the regulation of multi-
protein complexes in cells.  In addition to enzymic activity, many immunophilins act as molecular 
chaperones.  This property may be conferred by the isomerase domain and/or by additional domains.  
Recent years have seen a great increase in the number of known immunophilin genes in parasitic protozoa 
and helminths and in many cases their products have been characterized biochemically and their temporal 
and spatial expression patterns have been examined.  Some of these genes represent novel types: one 
example is a Toxoplasma gondii gene encoding a protein with both cyclophilin and FKBP domains.  Likely 
roles in protein folding and oligomerisation, RNA splicing and sexual differentiation have been suggested for 
parasite immunophilins.  In addition, unexpected roles in parasite virulence (Mip FKBP of Trypanosoma 
cruzi) and host immuno-modulation (e.g. 18-kDa cyclophilin of Toxoplasma gondii) have been established.  
Furthermore, in view of the potent antiparasitic activities of cyclosporins, macrolactones and non-
immunosuppressive derivatives of these compounds, immunophilins may mediate drug action and/or may 
themselves represent potential drug targets.  Investigation of the mechanisms of action of these agents may 
lead to the design of potent and selective antimalarial and other antiparasitic drugs.  This review discusses 
the properties of immunophilins in parasites and the 'animal model' Caenorhabditis elegans and relates 
these to our understanding of the roles of these proteins in cellular biochemistry, host-parasite interaction 
and the antiparasitic mechanisms of the drugs that bind to them. 
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Immunophilin is the collective name given to the cyclophilin and FK506-2 
binding protein (FKBP) families.  As the name suggests, these include the major 3 
binding proteins of certain immunosuppressive drugs: cyclophilins for the cyclic 4 
peptide cyclosporin A and FKBPs for the macrolactones FK506 and rapamycin.  Both 5 
families, although dissimilar in sequence, possess peptidyl-prolyl cis-trans isomerase 6 
activity in vitro and can play roles in protein folding and transport, RNA splicing and 7 
the regulation of multi-protein complexes in cells.  In addition to enzymic activity, 8 
many immunophilins act as molecular chaperones.  This property may be conferred 9 
by the isomerase domain and/or by additional domains.  Recent years have seen a 10 
great increase in the number of known immunophilin genes in parasitic protozoa and 11 
helminths and in many cases their products have been characterized biochemically 12 
and their temporal and spatial expression patterns have been examined.  Some of 13 
these genes represent novel types: one example is a Toxoplasma gondii gene encoding 14 
a protein with both cyclophilin and FKBP domains.  Likely roles in protein folding 15 
and oligomerisation, RNA splicing and sexual differentiation have been suggested for 16 
parasite immunophilins.  In addition, unexpected roles in parasite virulence (Mip 17 
FKBP of Trypanosoma cruzi) and host immuno-modulation (e.g. 18-kDa cyclophilin 18 
of Toxoplasma gondii) have been established.  Furthermore, in view of the potent 19 
antiparasitic activities of cyclosporins, macrolactones and non-immunosuppressive 20 
derivatives of these compounds, immunophilins may mediate drug action and/or may 21 
themselves represent potential drug targets.  Investigation of the mechanisms of action 22 
of these agents may lead to the design of potent and selective antimalarial and other 23 
antiparasitic drugs.  This review discusses the properties of immunophilins in 24 
parasites and the ‘animal model’ Caenorhabditis elegans and relates these to our 25 
 3 
understanding of the roles of these proteins in cellular biochemistry, host–parasite 1 
interaction and the antiparasitic mechanisms of the drugs that bind to them. 2 
 3 




1. Introduction 1 
The cyclophilin (CYP) and FK506-binding protein (FKBP) families, although 2 
unrelated in sequence, are often considered together because of their shared enzymic 3 
activities. Both cyclophilins and FKBPs, along with a smaller protein class, the 4 
parvulins, exhibit peptidyl-prolyl cis-trans isomerase (PPIase: EC 5.2.1.8) activity that 5 
plays a vital role in protein folding (Fischer and Aumüller, 2003). Although the 6 
peptide bonds of nascent polypeptides emerge from the ribosome in the trans-7 
conformation, and the majority retains that energetically-favoured state in fully-folded 8 
proteins, there is a significant minority (~5–7% of the proteins with structures solved) 9 
of peptidyl-prolyl (Xaa-Pro) bonds that switch to the cis-conformation during folding, 10 
transport and assembly.  The cis-trans isomerisation of Xaa-Pro bonds is one of the 11 
rate-limiting steps of protein folding. However, the influence of cyclophilins and 12 
FKBPs on the conformations, locations, oligomeric states and activities of various 13 
proteins in cells cannot be explained by PPIase activity alone.  At least some 14 
cyclophilins and FKBPs can act as molecular chaperones in an analogous manner to 15 
certain members of stress protein families.  The chaperone activity can be measured 16 
separately in vitro, for example via aggregation assays using model substrates, and 17 
may or may not be dependent on the presence of a functioning PPIase domain.  An 18 
additional property common to most eukaryotic and prokaryotic members of each 19 
family is their interaction with certain immunosuppressive drugs: the cyclic 20 
undecapeptide cyclosporin A (CsA) binds to cyclophilins, and the macrolactones 21 
FK506 and rapamycin to FKBPs.  For this reason, cyclophilins and FKBPs are known 22 
collectively as the immunophilins.  Binding of any of these immunosuppressants 23 
inhibits the PPIase activity of its respective partner.  Although this inhibition may 24 
have physiological consequences, it does not represent the mechanism of 25 
 5 
immunosuppressive action as such.  In T-lymphocyte suppression, CsA–cyclophilin 1 
or FK506–FKBP12 complexes form composite surfaces that strongly inhibit the 2 
protein phosphatase calcineurin, a crucial component of a Ca2+-dependent signalling 3 
pathway (Matsuda and Koyasu, 2000).  Calcineurin is also the relevant target in fungi, 4 
where inhibition of this phosphatase prevents recovery from pheromone-induced cell-5 
cycle arrest (Saccharomyces cerevisiae) or growth at elevated temperatures relevant 6 
to virulence (Cryptococcus neoformans) (Wang and Heitman, 2005).  In the case of 7 
rapamycin–FKBP, the relevant target is not calcineurin but the protein kinase TOR 8 
(target of rapamycin), and the downstream blockade is not on T-cell activation (G0 to 9 
G1 transition) but on proliferation (G1 to S).  Therefore immunophilins are not only 10 
involved in the folding, trafficking and activity of a range of cellular proteins, but also 11 
mediate the effects of certain pharmacologically-active small molecules.  Aside from 12 
their roles in cellular biochemistry, immunophilins of parasites are particularly 13 
interesting for two additional reasons.  First, there is evidence that some are involved 14 
in the pathogenesis of infections caused by protozoa and other microorganisms 15 
(Hacker and Fischer, 1993).  Second, CsA, FK506, rapamycin and more excitingly, 16 
nonimmunosuppressive analogues of these compounds, have strong inhibitory effects 17 
on certain parasites in culture and in animal models of infection (Bell et al., 1996).  18 
This review considers the properties of the well-characterised immunophilin genes 19 
and their products, focussing on their roles in host–parasite interaction and the 20 
antiparasitic actions of certain drugs.  The emphasis is on work published in the last 21 
ten years: for a fuller discussion of earlier work, see the reviews by Page et al. 22 
(1995b) and Bell et al. (1996). 23 
 24 
2. Cyclophilins 25 
 6 
2.1 Genes and gene expression (mRNA level) 1 
It is common that a given genome contains more than one cyclophilin gene – 2 
eight in S. cerevisiae and at least 16 in humans (Galat, 2003) – and this may also be 3 
the case for most parasites.  In this section we shall confine ourselves to those genes 4 
that are expressed and for which data of some functional relevance, e.g. PPIase or 5 
chaperone activity, cyclosporin binding, or specific distribution, have been obtained.  6 
Browsing of annotated genes in parasite genome databases reveals more putative 7 
cyclophilin or cyclophilin-like genes and more detailed data mining using conserved 8 
cyclophilin sequences can expose even more.  We shall refrain from speculating on 9 
sequences that may or may not encode actual cyclophilins, except where it is likely to 10 
be informative, e.g. where a clear orthologue of a well-characterised gene in one 11 
parasite species is found in the genome of a closely-related species. 12 
The properties of the protozoal cyclophilins for which there are firm, 13 
published expression and/or functional data are shown in Table 1.  The nomenclature 14 
we shall use for protozoal cyclophilins is similar to the convention of Galat (2003): 15 
cyclophilin is abbreviated to CYP and a species-specific prefix and, especially if there 16 
is more than one type in one organism, a suffix representing the approximate 17 
molecular mass in kDa of the mature protein (if known), are added, e.g. hCYP18 18 
(human 18-kDa cyclophilin, hCyPA), PfCYP19A (one of two Plasmodium 19 
falciparum cyclophilins of 19-kDa).  In general, the known cyclophilins of protozoal 20 
parasites are closely related in sequence to each other and to hCYP18, the first 21 
cyclophilin to be discovered and the one with which other cyclophilins are usually 22 
compared.  The residues known from three-dimensional structures to make close 23 
contact with CsA, especially the crucial tryptophan (position 121 in hCYP18), are for 24 
 7 
the most part well conserved in the protozoal cyclophilins (Fig. 1).  The appearance of 1 
the residues known to contact calcineurin in the presence of CsA is less consistent. 2 
Three cyclophilin genes have been identified in P. falciparum: Pfcyp19B 3 
(formerly PfCyP, PfCyP22: Hirtzlin et al., 1995), Pfcyp24 (formerly PFCyP: Reddy, 4 
1995) and  Pfcyp19A (formerly PfCyP19: Berriman & Fairlamb, 1998).  These genes 5 
are located on chromosomes 11, 8 and 3, respectively.  Aside from the N-terminal 6 
extensions of PfCYP19B and PfCYP24, the major difference between the 7 
P.falciparum cyclophilins and hCYP18 sequences lies in ‘insertions’ of 4–6 amino 8 
acids situated around position 43-44 (hCYP18 numbering; Fig. 1), which lies in the 9 
linker region between helix α1 and strand β3 (Dornan et al., 2003).  This corresponds 10 
to a region of substantial diversity among cyclophilins in general (Galat, 1999).  All 11 
three P. falciparum cyclophilins have orthologues encoded in the P. yoelii and P. 12 
berghei genomes (Carlton et al., 2002; Hall et al., 2005), PfCYP19A and PfCYP19B 13 
in the P. chabaudi genome (Hall et al., 2005) and PfCYP19A in P. vivax (Cui et al., 14 
2005).  Of these non-falciparum cyclophilins, only the P. berghei PfCyP19A 15 
orthologue has been characterised (Nunes, J., 2003. Cyclophilins and the antimalarial 16 
activity of cyclosporin A. PhD thesis. University of Dundee).  17 
All three P. falciparum cyclophilins are expressed at the mRNA level in 18 
erythrocytic parasites (Hirtzlin et al., 1995; Reddy, 1995; Bozdech et al., 2003; Le 19 
Roch et al., 2003): interestingly, Pfcyp24 mRNA is highest in the immature (ring) 20 
stages, Pfcyp19A mRNA in the middle of the erythrocytic cycle and Pfcyp19B mRNA 21 
in the more mature (late trophozoite/schizont) stages.  If these transcript levels are 22 
reflected in protein levels (which has been confirmed for PfCYP19B: Gavigan et al., 23 
2003) then this may imply some functional redundancy coupled with stage-24 
specificity. 25 
 8 
High et al. (1994) isolated genes encoding two Toxoplasma gondii 1 
cyclophilins, TgCYP18 (TgCyP18.5) and TgCYP20 (Fig. 1).  TgCYP20 was 2 
apparently part of a larger open-reading frame but the N-terminal amino acid of the 3 
mature protein corresponded to the beginning of a typical cyclophilin domain.  Both 4 
were highly similar to hCYP18 in the core region but TgCYP20 differed in its 7-5 
amino acid ‘insertion’ in the same region as in the P. falciparum cyclophilins.  The 6 
‘dual family’ FKBP–cyclophilin hybrid from T. gondii is discussed below.  A newly-7 
described cyclophilin of Neospora caninum, an apicomplexan pathogen of cattle, was 8 
highly similar to TgCYP18 (Tuo et al., 2005). 9 
Cyclophilin genes have been found in Leishmania major (Rascher et al., 1998) 10 
and L. donovani (Dutta et al., 2001).  Both had well-conserved CYP/CsA-binding 11 
domains.  The L.major protein LmCYP19 included an unusual 11-amino acid 12 
‘extension’ at the N-terminus and a 3-amino acid ‘insertion’ around residue 102, 13 
which is expected to fall in the linker between β-sheets 4 and 5 (Rascher et al., 1998).  14 
These features were conserved in the cyclophilins of various African trypanosomes 15 
(Dao-Thi et al., 1998; Pellé et al., 2002) and those of the South American 16 
trypanosome Trypanosoma cruzi (Búa et al., 2001) but not the signal-sequence-17 
containing one of L. donovani (Dutta et al., 2001).  Giardia intestinalis cyclophilin 18 
had an N-terminal ‘extension’ of similar length but unrelated sequence (Yu et al., 19 
2002). 20 
The last decade has witnessed an explosion in the database submissions of 21 
helminth immunophilin sequences and has been a direct output of ongoing expressed 22 
sequence tag (EST) and genomic sequence-based genome projects. This information 23 
explosion has been most dramatic for the free-living nematode Caenorhabditis 24 
elegans, which represents the first completed and annotated animal genome sequence 25 
 9 
(C. elegans genome consortium 1998, www.wormbase.org). The C. elegans genome 1 
resource has permitted the global analysis of the cyclophilin and FKBP families. As a 2 
direct consequence, more immunophilins have been characterized to date in this single 3 
organism than in any other: 18 separate cyclophilin isoforms and 8 separate FKBP 4 
isoforms (Tables 2 and 3; www.wormbase.org). This large gene expansion of the 5 
metazoan immunophilins over the protozoal ones reflects the comparative increase in 6 
complexity of the organisms. Many of the C. elegans immunophilins have been 7 
characterized with regards to their expression, functional significance (Page, 1997; 8 
Page and Winter, 1998, 1999; Dornan et al., 1999; Ma et al., 2002; Picken et al., 2002; 9 
Table 1) and activity (Page et al., 1996; Dornan et al., 1999; Picken et al., 2002). 10 
Information available for other helminth species has predominantly focused on a small 11 
number of genes per species, but as genome projects progress and become annotated 12 
this situation is expected to change rapidly. In addition to being a well-established 13 
animal model, C. elegans clearly represents an ideal nematode model system 14 
(Gilleard, 2004). The greatest advantage of the model system however, is the fact that 15 
global gene function (Kamath et al., 2003) and transcript location experiments (Hope 16 
et al., 1998) can be carried out with relative ease.  For these reasons, the C. elegans 17 
immunophilins will be used here as a framework into which the more limited 18 
information on parasitic helminth immunophilins will be organised.  This complete C. 19 
elegans sequence data allows the subgrouping of the C. elegans CYPs (and FKBPs: 20 
see below) into four major classes; type A, conserved cytosolic forms; type B, secreted 21 
forms; type C, mitochondrial forms and type D, non-secreted multi-domain or 22 
divergent forms.  The nomenclature used for helminth genes in this review follows the 23 
standard genetic nomenclature for C. elegans. 24 
 10 
There are three type-A cyclophilin genes in the C. elegans genome: cyp-2, -3 1 
and -7. Global RNAi experiments (Kamath et al., 2003) reported wild type phenotypes 2 
for reduced expression of all three isoforms, but one single experiment with cyp-7 3 
reported some associated embryonic lethality (www.wormbase.org).  From the 4 
parasitic helminths, direct orthologues of type-A cyclophilin genes have been cloned 5 
and sequenced from filarial nematodes (Ma et al., 1996), cestodes (Lightowlers et al., 6 
1989) and trematodes (Argeat, 1992; Klinkert et al., 1996; Kiang et al., 1996). In the 7 
case of the filarial species Onchocerca volvulus, Dirofilaria immitis and Brugia 8 
malayi, these are highly homologous to the C. elegans type-A isoforms.  In the 9 
trematode parasite Schistosoma mansoni, two separate type-A cyclophilins have been 10 
described, namely SmCypA  (Klinkert et al., 1996) and Smp17.7 (Kiang et al., 1996). 11 
The spatial expression patterns of the C. elegans A-type cyclophilins (at the 12 
transcript level) range from non-detectable for cyp-2 (Table 1) to exclusive expression 13 
in the excretory cell and duct (cyp-3) (Dornan et al., 1999; Fig. 2B). In addition, cyp-3 14 
is expressed predominately in larval stages.  The location in the excretory system is 15 
intriguing, and may indicate that CYP-3 is involved in the regulation of ion fluxes in 16 
analogy to the vertebrate renal system. 17 
The type-B secreted cyclophilins cyp-5 and -6 are well characterized in C. 18 
elegans and parasitic helminth type-B isoforms are also well represented in the 19 
database and literature, being found in B. malayi (accession number Q6ynz2), S. 20 
mansoni and S. japonicum (Klinkert et al., 1995, 1996). The RNAi studies on the 21 
secreted C. elegans cyclophilins failed to uncover any associated phenotype, either 22 
singly or in combination (Picken et al., 2002). C. elegans cyp-5 and -6 are both 23 
predominately expressed in the embryo, with expression also detected in larval and 24 
adult stages (Picken et al., 2002). Both isoforms are also expressed in the nematode 25 
 11 
gut (Picken et al., 2002; Table 2; Fig. 2A, F).  A type-C cyclophilin has been 1 
described in C. elegans (Page et al., 1996) but not yet in any parasitic helminth. 2 
The type D, divergent or multi-domain cyclophilins represent the largest and 3 
possibly most interesting class of CYPs in C. elegans. These isoforms 4 
characteristically have divergent CYP/CsA-binding domains and/or may also be 5 
flanked by additional non-cyclophilin domains. The divergent cyclophilins have 6 
reported or predicted roles as diverse as muscle protein folding, sexual differentiation 7 
of the germline, collagen folding and RNA splicing.  The divergent 3-domain isoform 8 
CYP-4 (Page and Winter, 1998), or cyp60, has orthologues in the filarial species B. 9 
malayi, O. volvulus  (Page and Winter, 1998) and D. immitis (Hong et al., 1998).  10 
CYP-4 is most abundant in the L1 stage and has strong somatic muscle cell 11 
expression pattern in C. elegans (Page and Winter, 1998; Table 2; Fig. 2D), with 12 
additional somatic and germline expression also being reported (Belfiore et al., 2004). 13 
This isoform has been hypothesized to be involved in proper muscle protein folding 14 
(Page and Winter, 1998) and is involved in the sexual differentiation of the 15 
hermaphrodite germ-line (Belfiore et al., 2004). The cyp-8 isoform represents a non-16 
essential gene in C. elegans, the transcript of which encodes two distinct domains; a 17 
divergent, but active, CYP domain (Page et al., 1996) and a large, C-terminal, 18 
charged, serine-rich domain that contains several functional nuclear location signals 19 
(Page and Winter, 1999). The transcript is expressed in all life-cycle stages but is 20 
confined spatially to the gut cell nuclei (Page and Winter, 1999; Table 1; Fig. 2C). 21 
Direct homologues of cyp-8 are to be found in the filarial nematode B. malayi (Page et 22 
al., 1995a), D. immitis and O. volvulus (Hong et al., 1998).  CYP-9 represents a two-23 
domain cyclophilin with an unusual transcriptional organization, being found in an 24 
operon with a second protein-folding enzyme, protein disulphide isomerase (pdi-1) 25 
 12 
(Page, 1997).  This conserved transcriptional organization is also found in the closely 1 
related nematode Caenorhabditis briggsae (Page, 1999). This arrangement of operons 2 
is characterized by downstream genes being trans-spiced to a distinctive SL2 leader 3 
sequence, and is found in 15% of all C. elegans transcripts (Blumenthal and Stewart, 4 
1997). Interestingly, 50% of the C. elegans cyclophilins are found in such operons 5 
(Blumenthal and Gleason, 2003). The enzymes encoded by cyp-9 and pdi-1 are 6 
hypothesized to cooperate in protein folding events, such as collagen trimerization. 7 
Both transcripts share a single promoter and are expressed in the cuticle-collagen 8 
synthesizing hypodermal tissues (Page, 1997).  No direct homologue of cyp-9 has to 9 
date been described in the parasitic helminths.  CYP-13 is the first of the divergent 10 
isoforms predicted to play a role in RNA splicing.  CYP-13 has an N-terminal RNA 11 
recognition motif (RRM) followed by a conserved CYP domain (Zorio and 12 
Blumenthal, 1999).  This non-essential divergent cyclophilin gene is in an operon 13 
with an essential RNA-splicing factor, uaf-2 (Zorio and Blumenthal 1999). A direct 14 
orthologue of cyp-13 was recently cloned from the parasitic nematode Haemonchus 15 
contortus (Valle et al., 2005). Likewise a cyp-13 orthologue is present in the 16 
trematode parasites S. japonicum (Zorio and Blumenthal, 1999) and S. mansoni (Valle 17 
et al., 2005) indicating an evolutionarily conserved role for this predicted splicing 18 
factor. Information regarding the final members of the divergent cyclophilins is 19 
limited to unpublished expression patterns and genome-wide RNAi studies (Table 2). 20 
From the global RNAi studies (Kamath et al., 2003) and the published studies 21 
summarized in Table 2, redundancy of function in this large gene family may 22 
contribute to the apparent lack of phenotype in knock-down parasites.  In 23 
Saccharomyces cerevisae, combined knock-outs of the cyclophilins and FKBPs 24 
revealed a high degree of functional redundancy  (Dolinski et al., 1997). 25 
 13 
2.2 Protein expression and locations 1 
In most eukaryotes there is a small, one-domain cyclophilin, like hCYP18, that 2 
is abundant in the cytosol.  In the case of P. falciparum, PfCYP19A is the likeliest 3 
candidate for the hCYP18 homologue (see Table 1).  It was found at ~1.2% of cellular 4 
protein in erythrocytic parasites and the available evidence suggests that it is cytosolic 5 
(Berriman and Fairlamb, 1998; Nunes, J., 2003. PhD thesis. University of Dundee; 6 
Gavigan et al., 2003).  The location of PfCYP19B is more problematic.  There was a 7 
cleaved signal sequence (Gavigan et al., 2003) but no obvious endoplasmic reticulum-8 
retention signal (Hirtzlin et al., 1995).  Unexpectedly, the protein appeared to be 9 
located predominantly in the cytosol, according to immunofluorescence microscopy 10 
and cell fractionation/western blotting (Gavigan et al., 2003).  PfCYP19B was also 11 
abundant in erythrocytic parasites at up to 0.5% of cellular protein and its highest 12 
copy number was in the mature, schizont stages (Gavigan et al., 2003).  The 13 
conundrum of PfCYP19B’s location has yet to be explained.  The long, asparagine-14 
rich, N-terminal extension of PfCYP24 (Reddy, 1995; Fig. 1) is an intriguing feature 15 
that appears not to be a typical signal sequence and is not closely related to any 16 
known non-Plasmodium sequences.  It is not known whether this extension is cleaved 17 
and the evidence for production of significant quantities of the protein in blood-stage 18 
parasites is still limited.  In Toxoplasma, TgCYP18 contained a signal sequence (High 19 
et al., 1994) and was secreted by tachyzoites to up to 2.4% of total protein in cell 20 
culture supernatant fluid (Aliberti et al., 2003).  Similarly, the related N. caninum 21 
cyclophilin, which also has a presumed signal sequence, was detected in both 22 
tachyzoite lysates and culture supernatants using antibody to TgCYP18 (Tuo et al., 23 
2005). 24 
 14 
The L. donovani cyclophilin LdCYP had a cleaved signal peptide and was 1 
found predominantly or exclusively in the particulate fraction (Dutta et al., 2001).  It 2 
was secreted in the presence of CsA, suggesting that CsA-sensitive binding to ER-3 
resident proteins might normally anchor it in the cell.  The cyclophilin of African 4 
trypanosomes, while predominantly cytosolic, was also found in culture supernatants 5 
(Pellé et al., 2002).  Although its role in host–parasite interaction is unknown, it is a 6 
major band on western blots probed with immune bovine sera and a major constituent 7 
of an immunosuppressive fraction of T. congolense parasites. 8 
The tissue-specific expression patterns of helminth cyclophilins have been 9 
determined mainly at the mRNA transcript level (see above and Fig. 2). In the case of 10 
C. elegans cyp-5 gut expression , this reporter transcript result was confirmed using 11 
specific antibodies (Picken et al., 2002).  S. mansoni P17.7 protein has been detected 12 
in the adult tegument and gut tissues (Kiang et al., 1996). Likewise, the expression of 13 
the S. mansoni CYP B protein was also restricted to the adult tegument and associated 14 
tubercles (Klinkert et al., 1995).   15 
2.3 Protein properties and functions 16 
PPIase activity has been demonstrated in vitro for the native and/or 17 
recombinant forms of several cyclophilins of protozoal parasites (Table 1).  In P. 18 
falciparum, all three cyclophilins exhibited PPIase activity.  Their substrates and/or 19 
binding partners are as yet unknown; however, PfCYP19A and PfCYP19B, but not 20 
PfCYP24, in complex with CsA were potent inhibitors of P. falciparum calcineurin in 21 
vitro (Dobson et al., 1999; Kumar et al., 2005b).  The three-dimensional structures of 22 
wild-type and a mutant PfCYP19A in complex with CsA were solved to 2.1Å 23 
resolution by Peterson et al. (2000).  The overall fold and interaction with CsA were 24 
 15 
virtually identical to those of hCYP18 except for an extension in the linker between 1 
helix α1 and strand β3 as mentioned above. 2 
LdCYP is a typical single-domain cyclophilin with PPIase activity (Dutta et 3 
al., 2001).  However, it also possessed an unusual chaperone action, in that it could 4 
rescue functional monomers of L. donovani adenosine kinase from non-functional, 5 
soluble aggregates or protect urea-denatured, refolding forms of this enzyme from 6 
aggregation in vitro (Chakraborty et al., 2002, 2004).  Adenosine kinase is unusual in 7 
forming soluble, non-functional aggregates in the absence of stress.  The activity was 8 
ATP-independent, unaffected by CsA, independent of PPIase activity and was 9 
associated with direct binding of LdCYP to the kinase.  Remarkably, the chaperone 10 
activity was maintained and even enhanced by deletion of the first 88 amino acids of 11 
the 166-amino acid (mature) LdCYP, indicating that the C-terminal part alone was 12 
sufficient.  Molecular modelling studies suggested that the explanation could lie in the 13 
higher exposure of crucial hydrophobic residues in the truncated form.  The effect of 14 
LdCYP on adenosine kinase was confirmed under more physiological conditions 15 
using an Escherichia coli co-expression system.  Its relevance to Leishmania biology 16 
is not yet known. 17 
The conserved A-type cyclophilins of C. elegans tested had significant PPIase 18 
activity against a defined synthetic substrate (Page et al., 1996).  The CYP-3 enzyme 19 
has been crystallized and its structure solved to 1.8Å resolution. This structure shows 20 
remarkable similarity to hCYP18 with the exception of an additional divergent 21 
exposed loop structure (Dornan et al., 1999).  Its PPIase activity and inhibition by 22 
CsA have also been demonstrated (Dornan et al., 1999). The recombinant B. malayi 23 
CYP A (Ma et al., 1996) and S. mansoni smp17.7 (Kiang et al., 1996) were also found 24 
to possess significant PPIase activity.  Among the type-B secreted cyclophilins, CYP-25 
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5 and -6 of C. elegans displayed potent PPIase activity (Page et al., 1996; Picken et 1 
al., 2002). In addition, CYP-5 has been structurally solved to 1.75Å and the structure 2 
of CYP-6 has been modeled on the CYP-5 structure (Picken et al., 2002) revealing 3 
high similarity but a significant negative charge difference on the CYP-6 surface.  The 4 
PPIase activity of the C-type C. elegans cyclophilin CYP-1 has likewise been 5 
confirmed (Page et al., 1996).  Among the D-type cyclophilins, CYP-4 has relatively 6 
low activity in the standard PPIase assay and this was a consistent observation for the 7 
remaining type D forms that have been analysed (CYP-8, -9, -10 and -11: Page et al., 8 
1996; Page and Winter 1998). The divergent cyclophilin domain of the B. malayi 9 
orthologue of the CYP-8 enzyme, BmCYP-1, is an active PPIase that is relatively 10 
insensitive to CsA (IC50 = 860 nM: Page et al., 1995).  This filarial parasite enzyme 11 
has been crystallized and solved to a resolution of 1.9Å (Taylor et al., 1998) and 12 
2.15Å (Mikol et al., 1998). These structural studies uncovered the molecular nature of 13 
the insensitivity of this divergent isoform to CsA, confirming that a mere two amino 14 
acid changes in the CsA-binding pocket relative to hCYP18 had a profound effect on 15 
its conformation and subsequent ability to bind to this drug (Page et al., 1995; Taylor 16 
et al., 1998).  Finally, the CYP-13 two-domain RRM cyclophilin orthologue from H. 17 
contortus has been expressed and characterized in both PPIase and RNA-binding 18 
assays (Valle et al., 2005). 19 
2.4 Roles in host-parasite interaction and pathogenesis 20 
T. gondii affects pro- and anti-inflammatory host cell signalling in such as way 21 
as to maximise parasite multiplication and spread while maintaining host survival 22 
(Denkers, 2003).  One aspect of this manipulation is the up-regulation of interleukin 23 
(IL)-12-dependent production of interferon (IFN)-γ that is critical to host survival of 24 
acute toxoplasmosis.  This effect appears to occur by two distinct pathways, one of 25 
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which is unique to T. gondii and involves triggering of the cysteine–cysteine 1 
chemokine receptor CCR5 in dendritic cells and macrophages by secreted T. gondii 2 
CYP18 (C-18: Aliberti et al., 2003).  TgCYP18, but not hCYP18 nor PfCYP19A, 3 
appears to induce IL-12 production by interacting directly with CCR5.  The effect was 4 
blocked by addition of CsA.  These observations implied that structural determinants 5 
related to CsA binding but peculiar to TgCYP18 were responsible for induction of IL-6 
12 synthesis.  This idea was confirmed by modelling of the TgCYP18 structure on 7 
that of PfCYP19A and site-directed mutagenesis of putatively surface-exposed 8 
residues that were absent in PfCYP19A (Yarovinsky et al., 2004).  Two of the 9 
TgCYP18 mutants had reduced interaction with CCR5 and reduced IL-12 induction 10 
but four separate mutants with reduced PPIase activity did not, further suggesting that 11 
PPIase activity was not required for the effect. TgCYP18 appears to act as a structural 12 
mimic of CCR5-binding ligands, albeit one with no sequence similarity to the known 13 
host ligands for this receptor.  There is also evidence that the Neospora cyclophilin 14 
NcCYP plays a role in stimulating IFN-γ production by bovine peripheral blood 15 
mononuclear cells and N. caninum-specific CD4+ T-cells (Tuo et al., 2005).  This 16 
effect is also blocked by CsA.  IFN-γ production induced by N. caninum tachyzoites 17 
is thought to be critical in controlling the acute phase of neosporosis. 18 
A potentially useful application of the findings on TgCYP18 results from the 19 
fact that CCR5 is, along with CXCR4, an important co-receptor for HIV-1 entry into 20 
host cells (Golding et al., 2003). TgCYP18 blocked HIV-1-envelope-dependent cell 21 
fusion and HIV-1 infectivity in that majority (R5 type) of viruses that use CCR5.  22 
This effect was presumably caused by competition of TgCYP18 with the HIV-1 23 
envelope glycoprotein gp120 for binding to CCR5.  Since this antiviral effect was also 24 
sensitive to the mutations in TgCYP18 that affected CCR5 binding, these data provide 25 
 18 
a basis for design of new antiviral agents based on TgCYP18 (Yarovinsky et al., 1 
2004).  The effect of TgCYP18 on HIV is distinct from that of human CYP18, which 2 
involves interaction with the capsid protein and incorporation into virions during 3 
assembly and occurs in virus strains that use both CCR5 and CXCR4 co-receptors.  4 
Any consequences of the immunomodulatory effect of TgCYP18 in T. gondii/HIV-1 5 
co-infections are at present unknown. 6 
2.5 Roles in antiparasitic drug action 7 
The potent activities of CsA and other cyclosporins against certain parasites 8 
have been widely noted (reviewed in Chappell & Wastling, 1992; Page et al., 1995b; 9 
Bell et al., 1996).  In most cases, it has been assumed that the mechanism of 10 
antiparasitic action of cyclosporins is analogous to what is believed to be the principal 11 
mechanism of immunosuppressive action, namely binding to one or more cyclophilins 12 
followed by inhibition of calcineurin by the drug–cyclophilin complex.  However, 13 
observations from some parasites, as discussed below, are not consistent with this 14 
model.  Moreover, in no case has either a clear functional role for calcineurin been 15 
identified or the essentiality of this phosphatase established (although this could be 16 
accounted for by the relative genetic intractability of most parasites).  It should at 17 
least be considered that the antiparasitic action of cyclosporins in some or all parasites 18 
might result from some other consequence of binding to cyclophilin that is unrelated 19 
to calcineurin, or from interaction with different molecules altogether.  The 20 
demonstrated effects of cyclosporins on P-glycoproteins and on the mitochondrial 21 
permeability transition pore in other cell types and the physiological consequences of 22 
these interactions (Borel et al., 1996) should caution us against assuming that 23 
calcineurin is necessarily the target of cyclosporins in parasites. 24 
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Cyclophilins of malarial parasites have been of particular interest in view of 1 
the especially potent and selective antimalarial activity of cyclosporins (reviewed in 2 
Bell et al., 1996) and of the cyclophilin-binding, linseed peptide cyclolinopeptide A 3 
and analogues (Bell et al., 2000).  Although cyclosporins themselves are unlikely to 4 
be developed as antimalarial agents, understanding their mechanisms of action might 5 
contribute to the development of non-cyclosporin agents that act in a similar way.  6 
The PPIase activity of extracts of P. falciparum was first demonstrated by Bell et al. 7 
(1994).  However, no correlation was found between PPIase inhibition and inhibitory 8 
potency against cultured parasites among a group of naturally-occurring and semi-9 
synthetic cyclosporins.  This observation was later confirmed using recombinant 10 
PfCYP19A (Berriman and Fairlamb, 1998) and PfCYP19B (Gavigan et al., 2003) 11 
instead of crude parasite extract.  Specifically, a non-immunosuppressive derivative of 12 
cyclosporin D, valspodar ([3’-keto-MeBmt]1 [Val]2-cyclosporin; SDZ PSC 833) was 13 
the most potent antimalarial agent (IC50 = 32 nM) but had low affinity for cyclophilins 14 
(Bell et al., 1994).  Since valspodar was a particularly good inhibitor of mammalian 15 
P-glycoprotein, and was more potent than CsA in this respect, it was suggested that a 16 
P. falciparum P-glycoprotein homologue might be the relevant molecular target (Bell 17 
et al., 1996).  However, it has not been shown that any such protein is directly 18 
affected by cyclosporins.  Gavigan and Bell (2003) have recently shown that CsA 19 
susceptibility of P. falciparum can be influenced by the genotype and expression level 20 
of pfmdr1, which encodes P-glycoprotein homologue 1 (Pgh1) – but this effect may 21 
be indirect. 22 
A similar situation exists in T. gondii except that this parasite is not as 23 
susceptible to cyclosporins as Plasmodium.  Silverman et al. (1997) found no 24 
correlation between growth inhibition and cyclophilin binding among a series of 25 
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cyclosporins.  The most potent inhibitor, SDZ 215-918, did not bind to cyclophilins 1 
but inhibited rhodamine efflux, which may be a function of P-glycoprotein activity.  It 2 
was hypothesised that a T. gondii P-glycoprotein was the likely molecular target of 3 
CsA.  However, isolation of cyclosporin-binding proteins on affinity columns yielded 4 
only cyclophilins TgCYP18 and TgCYP20 (High et al., 1994).  It would be relevant 5 
to ask whether the cyclophilin-bound, or only free, CsA inhibits the P-glycoprotein, 6 
otherwise the role of cyclophilins might be to reduce the concentration of free CsA 7 
available and thus antagonise the action of the drug. 8 
Returning to malaria, three recent findings have put the spotlight back on 9 
cyclophilins (and calcineurin) as possible mediators of the action of CsA.  The first 10 
study identified cyclophilins PfCYP19A and PfCYP19B (but not P-glycoprotein) as 11 
the major cyclosporin-binding proteins of P. falciparum (Gavigan et al., 2003).  The 12 
second was the demonstration in parasite fractions and as a recombinant protein of a 13 
P. falciparum calcineurin that was able to dephosphorylate proteins and was 14 
inhibitable by CsA in combination with PfCYP19A or PfCYP19B (Dobson et al, 15 
1999; Kumar et al., 2004, 2005b).  The third was the demonstration that, of nine 16 
independently-isolated CsA-resistant mutants of P. falciparum, two had mutations in 17 
Pfcyp19A, one in Pfcyp19B and one in each calcineurin subunit-encoding gene 18 
(Kumar et al., 2005b).  A recombinant form of one of the altered PfCYP19A’s 19 
(W128C) was bound by CsA but the combination was a poor inhibitor of calcineurin.  20 
Both calcineurin lesions were associated with CsA-resistant phosphatase activity.  It 21 
would be informative to observe the effects of CsA and valspodar on transgenic 22 
parasites with overexpression, mutation or knock-out of the cyclophilin or calcineurin 23 
genes, if such parasites were viable. 24 
 21 
The Leishmania species so far investigated are relatively resistant to CsA 1 
although they possess cyclophilin and calcineurin (Rascher et al., 1998; Banerjee et 2 
al., 1999; Dutta et al., 2001).  Some authors have felt it necessary to explain this low 3 
susceptibility in terms of inability of the CsA–cyclophilin complex to bind to 4 
calcineurin (Rascher et al., 1998) or lack of abundance of cyclophilin in the cytosol 5 
(Dutta et al., 2001).   6 
There has been little discussion of the idea that cyclophilins per se could be an 7 
antiprotozoal drug target. The low human toxicity of certain cyclosporins (Bell et al., 8 
1996) and the observation that the homologue of hCYP18 is not required for viability 9 
of mice (Colgan et al., 2004) are some indication of the potential for selective toxicity 10 
to parasites.  In malaria, the activity of another non-immunosuppressive cyclosporin, 11 
[MeVal4]-CsA, which is a strong cyclophilin binder but whose complex with 12 
cyclophilins has very low affinity for calcineurin (Bell et al., 1994), suggests that 13 
cyclophilin might be a valid target in Plasmodium.  The anti-nematode effects of CsA 14 
include strong and consistent moulting and structural defects in C. elegans when this 15 
drug is applied at relatively high concentrations (Page et al., 1995b).  This effect is 16 
consistent with this compound inhibiting an endogenous PPIase that may be involved in 17 
gut or cuticle structural protein folding events.  However, it is well established that C. 18 
elegans routinely requires drug concentration up to one thousand-fold higher than 19 
those effective against mammalian cells (Rand and Johnson, 1995). In view of the 20 
negative RNAi studies of cyclophilin function described above, it is difficult to identify 21 
a specific C. elegans cyclophilin that is involved in this effect.  The possible functional 22 
redundancy in the cyclophilin gene family could be a confounding factor; for example 23 
the effect of CsA may be elicited by binding to a combination of the gut-expressed 24 
secreted isoforms CYP-5 and CYP-6 and the hypodermally-expressed form CYP-9. 25 
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Until stable double and triple mutants are available for these genes, the nature of the 1 
CsA target will remain elusive. Filarial parasites also express large mutigene 2 
cyclophilin families (see above) that may also be functionally redundant.  Elucidating 3 
the role they play in biological processes, including the synthesis of the cuticle, will 4 
be further complicated by the fact that reproducible RNAi techniques have not yet 5 
been widely adopted in these parasites.  Likewise, a hallmark of CsA-induced toxicity 6 
to cestode and trematode parasites is tegumental surface damage (Chappell et al., 7 
1993; Page et al., 1995b; McLauchlan et al., 2000).  It may be hypothesized that the 8 
phenotypes are elicited via inhibition of structural protein folding events but there was 9 
no correlation between anti-schistosomal properties and PPIase inhibition in a series 10 
of cyclosporins (Khattab et al., 1998).  In light of these observations, it would be 11 
worthwhile investigating the antiparasitic activities of a range of cyclophilin ligands 12 
that do not form calcineurin-inhibitory complexes. 13 
 14 
3. FK506-binding proteins (FKBPs) 15 
3.1 Genes and gene expression (mRNA level) 16 
As is the case for cyclophilins, several isoforms of FKBPs are usually found 17 
within the same organism. The first FKBP to be identified in the Apicomplexa was a 18 
35-kDa FKBP in P. falciparum (Braun et al., 2003). Analysis of the P.  falciparum 19 
genome database revealed PfFKBP35 to be the only obvious FKBP gene (Monaghan 20 
and Bell, 2005; Kumar et al, 2005a).  PfFKBP35 contained not only a conventional 21 
FKBP domain but also an additional domain containing three tetratricopeptide repeat 22 
(TPR) regions (Monaghan & Bell, 2005; Fig. 3).  TPR regions are rich in α-helix and 23 
have been associated with protein–protein interactions.  Analysis of the genomes 24 
(Carlton et al., 2002; Cui et al., 2005; Hall et al., 2005) of other Plasmodium species 25 
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including P. vivax indicates the presence of a single FKBP gene with remarkable 1 
similarity to PfFKBP35, though these genes are not yet known to be expressed. 2 
Likewise, only a single FKBP gene has been found in T. gondii.  This gene 3 
encoded not a PfFKBP35 orthologue but a protein belonging to an intriguing new 4 
family of immunophilins (Adams et al., 2005) that contained both an FKBP domain 5 
and a CYP domain separated by TPR regions (Fig. 3).  Similar ‘dual-family’ 6 
immunophilin genes could only be found in two bacterial species.  The authors of this 7 
study proposed the name FCBP (FK506- and cyclosporin-binding protein) for these 8 
novel proteins.  TgFCBP57 appears to be essential for growth of T. gondii, as judged 9 
by RNA interference (Adams et al., 2005). 10 
Trypanosoma cruzi contains an FKBP homologue belonging to the Mip sub-11 
family (Moro, 1995).  This particular sub-family was first identified in the obligate 12 
intracellular bacterium Legionella pneumophila, where it was shown to play a role in 13 
survival within human macrophages, leading to the designation macrophage 14 
infectivity potentiator (Mip – Cianciotto et al., 1989). Mips have also been identified 15 
in other intracellular pathogens, but TcMip is the only protozoal one identified to 16 
date.  17 
Experimental data on FKBPs from C. elegans (fkb genes) and the parasitic 18 
helminths are also relatively sparse in comparison to the cyclophilins. Information is 19 
summarized for C. elegans and used as a comparative system for the parasitic 20 
nematodes in table 3. The FKBP family also comprises cytosolic (A forms), secretory 21 
pathway (B forms) and divergent, multi-domain forms (D forms). 22 
Two separate genes encode the conserved cytosolic isoforms in C. elegans, 23 
namely the single FKBP-domain isoform gene fkb-2 and the dual FKBP-domain 24 
protein gene fkb-8. These genes are closely arranged (approximately 1 kb apart) on 25 
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chromosome I.  fkb-8 probably arose through a recent gene duplication event, a theory 1 
supported by its absence from the genome of the close relative C. briggsae (Table 3). 2 
FKB-2 has direct orthologues in  B. malayi (accession number Q9U8J7) and S. 3 
mansoni (Rossi et al., 2002; Knobloch et al., 2004) but orthologues of FKB-8 have yet 4 
to be detected. The SmFKBP12 isoform is expressed in all life-cycle stages (Rossi et 5 
al., 2002) and its transcript was detected by in situ hybridization in the female gonad 6 
and in the tegument of both sexes (Knobloch et al., 2004). 7 
There are numerous (50% of total) secreted (B-) isoforms of FKBP encoded in 8 
the C. elegans genome, all with a secretory signal peptide and a conserved ER 9 
retention signal (FKB-1, -3, -4 and -5). FKB-1 (a.k.a. FKBP-13) is a small single-10 
domain isoform having direct orthologues in the filarial species B. malayi, D. immitis 11 
and O. volvulus (Ma et al., 1999).  The remaining ER-resident forms FKB-3, -4 and -5 12 
all have two FKBP domains. Direct orthologues of FKB-3, -4 and -5 have not yet 13 
been described in any parasitic helminth species. 14 
The divergent (D-) isoforms characteristically have additional non-FKBP 15 
domains and two members are expressed in C. elegans. FKB-6 is the C. elegans 16 
equivalent of the functionally significant FKBP51/52, a steroid-receptor-associated, 17 
Hsp-90 binding co-chaperone (Riggs et al., 2003). This isoform possesses the 18 
characteristic TPR domains (Table 3). Direct orthologues of this isoform exist in B. 19 
malayi (accession number Q86M29) and S. mansoni (Osman et al., 1995).  The final 20 
C. elegans type-D isoform, FKB-7, has a signal peptide, a single FKBP domain and 21 
two EF-hand domains (Table 3). No parasite orthologues have thus far been described 22 
for FKB-7.  From the FBKP family, only fkb-6 has been attributed an RNAi 23 
phenotype from the genome-wide screens, being variably embryonic lethal in C. 24 
elegans (Table 3; www.wormbase.org). 25 
 25 
3.2 Protein expression and locations 1 
PfFKBP35 is expressed throughout the intraerythrocytic life cycle (Kumar et 2 
al, 2005a). Immunofluorescent studies showed that, during the ring stage, PfFKBP35 3 
is predominantly cytosolic, but as the parasites mature into trophozoites and 4 
schizonts, a significant amount of the protein is observed in the nucleus.  The bacterial 5 
Mip homologues so far studied are all surface bound proteins, whereas the T. cruzi 6 
homologue TcMip is secreted (Moro et al., 1995). The processed form of this protein 7 
is 18.8 kDa in size and is secreted predominantly by the invasive trypomastigote 8 
form. 9 
3.3 Protein properties and functions 10 
The modular structure of PfFKBP35 comprises an N-terminal FKBP domain 11 
followed by a tripartite TPR domain. With the exception of an additional C-terminal 12 
cyclophilin domain, the domain architecture of TgFCBP57 is similar to that of 13 
PfFKBP35  (Adams et al., 2005; Fig. 3). The modular structures of these proteins, and 14 
in particular the presence of TPR motifs, suggest that their primary functions may be 15 
in protein trafficking as part of large hetero-oligomeric complexes.  Human FKBP51 16 
and hFKBP52 are known to form part of oligomeric complexes comprising various 17 
chaperones and co-chaperones (Pratt and Toft, 2003). Genome analysis suggests that 18 
P. falciparum contains the complete set of chaperone (namely, Hsp40, Hsp70 and 19 
Hsp90) and co-chaperone components (namely, Hop and p23) necessary for such 20 
complexes (Monaghan, P., 2004. Identification and characterisation of an FK506-21 
binding protein from Plasmodium falciparum. PhD thesis, University of Dublin). 22 
PfHsp90 and PfHsp70 were recently shown to be present as part of large complexes 23 
of up to 300 kDa (Banumathy et al., 2003) and an interaction between PfFKBP35 and 24 
PfHsp90 was recently reported (Kumar et al, 2005b).  The finding that PfFKBP35 25 
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translocates to the nucleus from the cytoplasm lends further support for such a role 1 
(Kumar et al, 2005a). Alternatively, or perhaps additionally, PfFKBP35 could serve 2 
an important role in the folding of proteins, either as a folding catalyst, a chaperone, 3 
or both.  Studies of recombinant PfFKBP35 showed that PPIase activity was 4 
conferred by the FKBP domain and chaperone activity by both FKBP and TPR 5 
domains (Monaghan and Bell, 2005).  The finding that PfFKBP35 can inhibit 6 
calcineurin in the absence of FK506 is highly unusual (Monaghan and Bell, 2005; 7 
Kumar et al, 2005a).  Human FKBP38, which is suggested to regulate important 8 
cellular processes by modulating the activity of calcineurin, is the only other FKBP 9 
for which this phenomenon has been reported (Shirane and Nakayama, 2003), though 10 
this has recently been disputed (Weiwad et al., 2005).  The domain architecture of 11 
hFKBP38 and PfFKBP35 is strikingly similar.   12 
Analysis of the crystal structure of a mercaptopyruvate sulphurtransferase 13 
from Leishmania major has revealed an intriguing new FKBP-like protein. 14 
Sulphurtransferases are widely distributed throughout biology, but those of L. major, 15 
L. mexicana, T. cruzi and T. brucei posses unusual C-terminal extensions not known 16 
in any other sulphurtransferases (Williams et al., 2003) and the C-terminal extension 17 
of the L. major protein (LmMST) was recently shown to have remarkable structural 18 
similarity to an FKBP domain (Alphey et al., 2003). The primary sequence similarity 19 
between hFKBP12 and this C-terminal extension is quite low, and no PPIase activity 20 
was detected in a recombinant form of LmMST.  However, the finding that LmMST 21 
folds independently, unlike most other sulphurtransferases which require molecular 22 
chaperones, suggests that this FKBP-like extension acts as an in-built chaperone, 23 
stabilizing the overall folding of the protein. Indeed, truncated forms of LmMST, 24 
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devoid of the FKBP-like region, lose their inherent ability to fold in the absence of 1 
exogenous chaperones (Williams et al., 2003). 2 
The crystal structure of TcMip, solved at 1.7 Å, showed that with the 3 
exception of an extra β-strand, the overall fold was typical of FKBPs.  The FKBP 4 
domain is flanked at either end by exposed α-helices.  An N-terminal α-helix is also 5 
present in the L. pneumophila Mip but the C-terminal one is unique to TcMip (Pereira 6 
et al., 2002). 7 
 The S. mansoni SmFKB12 isoform is enzymically active and is inhibited by 8 
rapamycin, but S. mansoni parasites are resistant to this drug (Rossi et al., 2002). An 9 
enzymically active form of the C. elegans FKB-6 called p50 has also been 10 
characterized in S. mansoni (Osman et al., 1995). 11 
3.4 Roles in host-parasite interaction and pathogenesis 12 
Unlike the L. pneumophila Mip, which is involved in the ability of the 13 
bacterium to survive within its host cell, TcMip appears to function in the process of 14 
host cell penetration. The addition of a recombinant form of TcMip, produced 15 
heterologously in E. coli, was shown to enhance invasion of cultured simian epithelial 16 
or HeLa cells by trypomastigotes (Moro et al., 1995).  Infectivity was greatly reduced 17 
by antibodies to TcMip or by either FK506 or its non-immunosuppressive derivative, 18 
L685,818.  The latter compound was also able to protect mice from lethal infection by 19 
T. cruzi (Oz et al., 2002). 20 
3.5 Roles in antiparasitic drug action 21 
FK506 and/or rapamycin inhibit the growth of P. falciparum, T. gondii and T.  22 
cruzi in culture (Bell et al., 1994; Moro et al., 1995; Monaghan and Bell, 2005; 23 
Adams et al., 2005).  From the point of view of correlating the anti-parasitic activity 24 
of FK506 and related compounds with effects on the activity of these proteins, each of 25 
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the protozoal FKBPs characterised so far shows significant conservation of the 1 
fourteen residues that have been shown in hFKBP12, the archetypal FKBP, physically 2 
to contact FK506 (Kay, 1996).  There are at least two possible models, analogous to 3 
those discussed for cyclosporins above, by which FK506 and rapamycin could exert 4 
growth inhibitory effects through parasite FKBPs.  The first model, by analogy with 5 
the current models of immunosuppressive action of these drugs, is that the compounds 6 
combine with the FKBP, and together the drug–receptor complexes inhibit an 7 
essential parasite target. For FK506, as for CsA, the target in T-lymphocytes is 8 
calcineurin (Matsuda & Koyasu, 2000), while the hFKBP12-rapamycin complex 9 
inhibits the protein serine/threonine kinase TOR (Lorberg and Hall, 2004). However, 10 
the effects of non-immunosuppressive analogues of FK506 on the growth of P. 11 
falciparum in culture (Monaghan et al., 2005) and the finding that PfFKBP35 12 
inhibited the phosphatase activity of both bovine and P. falciparum calcineurin in the 13 
absence of FK506 (Monaghan and Bell, 2005; Kumar et al., 2005a), suggest that 14 
calcineurin is not involved in mediating the anti-malarial effects of FK506 and its 15 
analogues. Likewise, the lack of any obvious P. falciparum TOR homologue suggests 16 
that the anti-malarial actions of rapamycin are distinct from its immunosuppressive 17 
actions.  A second possible model by which these inhibitors could exert their 18 
antimalarial effects is through direct inhibition of the biochemical activity of the 19 
FKBPs.  Although the PPIase activity of recombinant PfFKBP35 is inhibited by 20 
FK506 (Monaghan and Bell, 2005), a study of FK520 (a compound identical to 21 
FK506 except for a change at C-21 from allyl to ethyl) and a number of synthetic non-22 
immunosuppressive analogues suggested that anti-chaperone activity correlated better 23 
with antimalarial activity (Monaghan et al., 2005). This finding leads us to consider 24 
whether the PPIase activity of PfFKBP35 has any physiological significance.  It is 25 
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known that all detectable PPIase activity in lysates of P. falciparum is inhibited by 1 
CsA (Bell et al., 1994) suggesting that the PPIase activity of parasite cyclophilins is 2 
more physiologically relevant. This was also shown for S. mansoni extracts (Khattab 3 
et al, 1998). The FKBP-like region of LmMST is devoid of enzymic activity yet 4 
appears to play an important role as a chaperone (Alphey et al., 2003). Indeed, the 5 
biological significance of the PPIase activity of certain other FKBPs remains 6 
controversial as their functions appear to be independent of PPIase activity (Galat, 7 
2003; Shirane and Nakayama, 2003). 8 
 9 
4. Conclusions and prospects 10 
The number of known immunophilins in parasites has expanded enormously 11 
since this topic was last reviewed (Page et al., 1995b; Bell et al., 1996).  Genome 12 
sequencing and expression sequence tag projects have played a major part in that 13 
expansion, a point well illustrated by the completed and annotated genome of the 14 
model nematode, C. elegans and several parasitic protozoa.  However, many more are 15 
expected to be discovered in the incompletely sequenced genomes.  Furthermore, the 16 
detailed assembly, annotation and characterisation of the gene products encoded by 17 
many of the sequences of interest has lagged behind their discovery.  Nonetheless, 18 
recombinant production and biochemical characterisation of parasite immunophilins 19 
is relatively straightforward, so in several cases we know of the PPIase activities and 20 
the effects of ligand binding, and in some cases chaperone activity has been 21 
demonstrated.  Studies of temporal expression and subcellular and tissue location 22 
have also been possible. The detailed structural characterizaton of certain members of 23 
the protozoal, filarial and C. elegans cyclophilin family members has uncovered many 24 
unusual features; including exposed divergent loops on the conserved forms, exposed 25 
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charge difference in the secreted forms and amino acid changes that clearly affect the 1 
binding of CsA and thus its inhibitory properties.  Overall the data from helminth 2 
parasites indicates an important role for these enzymes in structural protein folding 3 
but understanding of the functions of protozoal cyclophilins is still fragmentary. For 4 
the FKBPs, proposed roles in protein folding, steroid receptor function, signal 5 
transduction and co-chaperone functions can all be envisaged and are awaiting 6 
experimental confirmation.  Screening for protein–protein interactions and genetic 7 
manipulation can in the near future be expected to help expose the potentially 8 
manifold roles of parasite immunophilins. 9 
Certain immunophilins have been shown to play crucial roles in host–parasite 10 
interaction.  In the case of TgCYP18 this has enhanced understanding of, and perhaps 11 
the ability to manipulate, host immune signalling; in the case of TcMip, a virulence 12 
factor and possible target for therapeutic intervention has been found.  It seems likely 13 
too that immunophilins will be crucial to the correct folding and transport of other 14 
virulence factors, for example the adhesive proteins exported to the host erythrocyte 15 
by P. falciparum. 16 
Findings of potent and selective antiparasitic activity of non-17 
immunosuppressive derivatives of the immunophilin-binding drugs CsA and 18 
FK506/FK520 have led to much interest in immunophilins as possible drug targets.  19 
Whether the immunophilins themselves are the relevant targets or are components of 20 
drug–receptor complexes that inhibit other target molecules such as calcineurin has 21 
not yet been clearly established for any parasite, and may vary from species to 22 
species.  These non-immunosuppressive derivatives are clearly promising 23 
antiparasitic leads but they are large molecules with Mr of ~800-1200.  Investigation 24 
of the antiparasitic properties of lower-Mr immunophilin ligands would seem to be 25 
 31 
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 4 
Legends to figures 5 
Fig. 1. Multiple amino acid sequence alignment of protozoal cyclophilin domains 6 
with human CYP18 performed using ClustalW 1.8.2 (www.ebi.ac.uk).  The N-7 
terminal end of the TgCYP20 open-reading frame and the FKBP and tetratricopeptide 8 
repeat domains of TgFCBP57 have been left out.  Regions not found in the mature 9 
proteins, e.g. known signal peptides, are shown in bold.  Blocks of identical amino 10 
acids are shaded in black and conserved amino acids in grey.  The amino acids that 11 
contact CsA in the hCYP18–CsA complex are marked * and those that contact 12 
calcineurin in the hCYP18–CsA–calcineurin complex, # (Ke and Huai, 2004).  For 13 
accession numbers and gene product names, see Table 1. 14 
Fig. 2. Specific tissue location of a subset of Caenorhabditis elegans cyclophilins. 15 
A, Secretory pathway cyclophilin, CYP-6, located in the embryonic gut.  B, 16 
Cyclophilin A homologue, CYP-3, is located in the excretory cell and duct in adult 17 
stage worms. C, Adult gut location of divergent multi-domain cyclophilin isoform, 18 
CYP-8.  D, Divergent multi-domain cyclophilin, CYP-4, located in adult somatic 19 
muscle cells. E, DAPI-stained adult worm highlighting all nuclei. F, β-galactosidase 20 
stained worm in E revealing the gut cell location of the secreted isoform CYP-5.  All 21 
images depict transgenic C. elegans worms, transformed with promoter::lacZ reporter 22 
constructs. Constructs encode a nuclear location signal to aid cell identification. 23 
Worms were fixed and stained with β-galactosidase and viewed microscopically via 24 
differential interference contrast optics. The lengths of adult worms and embryos are 25 
 44 
typically 1 mm and ~70 µm, respectively.  See Dornan et al., 1999; Page and Winter 1 
1998, 1999; Picken et al., 2002 for more detail. 2 
Fig. 3. The modular structures of the FKBPs from Plasmodium falciparum and 3 
Toxoplasma gondii are strikingly similar to those of certain well-characterized human 4 
FKBPs. Accession numbers are given in parentheses.5 
 45 
Table 1. Properties of cyclophilins of protozoal parasites 1 
 2 
Protein Gene Additional Expression Expression Subcellular PPIase CsA References 3 
namea accession sequence (mRNA)b (protein)c location activityd binding 4 
 number motifs        5 
           6 
PfCYP19B X85956, signal C, N, M W, F mainly R (kcat/Km  = IC50 = 10 nM Hirtzlin et al., 1995 7 
 PF11_0164 sequence   cytosolic 2.3 µM-1s-1)  Gavigan et al., 2003 8 
        Bozdech et al., 2003 9 
        Le Roch et al., 2003 10 
 11 
PfCYP24 PF08_0121 N-terminal N, M F nd e Rf  Yese Reddy, 1995 12 
  extension      Bozdech et al., 2003 13 
        Le Roch et al., 2003 14 
        Florens et al., 2002 15 
 16 
PfCYP19A U33869, – C, M W, F probably R (kcat/Km  = Ki = 6.9 nM Berriman and Fairlamb, 1998 17 
 PFC0975c    cytosolic 12 µM-1s-1)  Gavigan et al., 2003 18 
        Bozdech et al., 2003 19 
        Le Roch et al., 2003 20 
 21 
PbCYP19 CAH98501 – C F nd R (kcat/Km  = nd Nunes, 2003g 22 
                                                 
a Species abbreviations in protein names are as follows: Pf, Plasmodium falciparum; Pb, P. berghei; Tg, Toxoplasma gondii; Nc, Neospora caninum; Lm, Leishmania major; 
Ld, L. donovani; Tb, Trypanosoma brucei; Tc, T. cruzi; Gi, Giardia intestinalis; Eh, Entamoeba histolytica. 
b C, cDNA clone; N, northern blot; M, microarray; R, reverse transcriptase PCR 
c P, purified protein; W, western blot; F, peptide mass fingerprint 
d N, native protein isolated from parasite; R, recombinant protein 
e nd, not determined 
f Impure protein preparation 
g Nunes, J., 2003. PhD thesis. University of Dundee. 
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      1.93 µM-1s-1)  Hall et al., 2005 1 
 2 
TgCYP18 U04633 signal C P, F secreted N, R (kcat/Km IC50 = 32 nM High et al., 1994 3 
  sequence    = 14 µM-1s-1)  Aliberti et al., 2003 4 
        Cohen et al., 2002 5 
 6 
TgCYP20 U04634 – C P, F nd N IC50 = 5 nM High et al., 1994 7 
        Cohen et al., 2002 8 
           9 
   10 
TgFCBP57 AAX51680 FKBP  C nd nd R IC50 = Adams et al., 2005 11 
  domain; TPR     750 nMh  12 
 13 
NcCYP CF422590 signal C F, W secreted nd nd Tuo et al., 2005 14 
  sequence 15 
         16 
LmCYP19 Y13576 – C W nd R (kcat/Km  = Ki = 5.2 nM Rascher et al., 1998 17 
      1.5 µM-1s-1)  18 
 19 
LdCYP AF158368 signal R W particulate R (kcat/Km  = Kd = 135 nM Dutta et al., 2001 20 
  sequence   fraction 6.3 µM-1s-1)  21 
 22 
TbCYP19 Tb11.03.0250 – C, N W cytosol, nd nd Pellé et al., 2002 23 
     flagellum, 24 
     secreted 25 
 26 
TcCYP19 AF191832 – C nd nd R IC50 = Búa et al., 2001 27 
       18.4 nM 28 
                                                 
h Isolated CYP domain 
 47 
 1 
GiCYP – – C, N nd nd R Yes Yu et al., 2002 2 
 3 
EhCYP AF017993 – C, N nd nd R Yes Ostoa-Saloma et al., 2000 4 
 48 








Expression pattern Parasitic helminth homologue 
cyp-1 Y49A3A.5 (V) C Y Wt All cellsa - 
cyp-2 ZK520.5 (III) A Y Wt No patterna Onchocerca volvulus cyp-2, Dirofilaria 
immitis cyp-2, Echinococus granulosus 
cypA 
cyp-3 Y75B12B.5 (V) A Y Wt Excretory system O. volvulus cyp-2, D. immitis cyp-2, 
Brugia malayi cyp-2 
cyp-4 F59E10.2 (II) D Y Wt/Mog/Dpy Body wall muscle  
Somatic and gonad 
B. malayi  cyp-4, D. immitis cyp-3, O. 
volvulus cyp-4 
cyp-5 F31C3.1 (I) B Y Wt Gut, pharynx & body wall 
muscle 
B. malayi SM7  (Q6ynz2) 
cyp-6 F42G9.2 (III) B Y Wt Gut Schistosoma mansoni cyp-B, S. 
japonicum  cypB (Q5d8j4), B. malayi 
SM7  
cyp-7 Y75B12B.2 (V) A Y Wt/Emb nd O.volvulus cyp-2, D. immitis cyp-2, B. 
malayi cyp-2 
cyp-8 D1009.2 (X) D Y Wt Gut B.malayi cyp-1, O.volvulus cyp-1,  
D.immitis cyp-1 
cyp-9 T27D1.1 (III) D Y Wt Hypodermis - 
cyp-10 B0252.4 (II) D Y Wt Excretory cella - 
cyp-11 T01B7.4 (II) D Y Wt Somatic musclea - 
cyp-12 C34D4.12 (IV) D Y Wt Guta - 
cyp-13 Y116A8C.34 
(IV) 
D Y Wt nd Haemonchus contortus Cyp,  S. 
japonicum (Q5der2) 
cyp-14 F39H2.2 (I) D Y Wt/Emb/Let nd - 
cyp-15 Y87G2A.6 (I) D Y Wt nd - 
 49 
cyp-16 Y17G7B.9 (II) D Y Wt Gut O. volvulus cyp-16 
cyp-17 ZC250.1 (V) D Y Wt nd - 
cyp-18  Y17G9B.4 (IV) D N Wt nd - 
Information based on C. elegans Wormbase version 145. Phenotypes: Wt = wild-type; Mog = maternalization of germline; Dpy = dumpy; Emb 1 
= embryonic lethal; Let = larval lethal.  Y=yes; N=no; nd = not determined. 2 
aPage, A.P. (unpublished data).  3 
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Expression pattern Parasitic helminth homologues 
fkb-1 F36H1.1 (IV) B Y Wt Gut Brugia malayi fkbp13, Dirofilaria immitis 
fkbp13, Onchocerca volvulus fkbp13 
fkb-2 Y18D10A.19.1(I) A Y Wt All cells B. malayi fkb12 
fkb-3 C05C8.3 (V) B Y Wt Hypodermis B. malayi fkb18 fragment (Q9u8j8) 
fkb-4 ZC455.10 (V) B Y Wt  No expression - 
fkb-5 C50F2.6 (I) B Y Wt Hypodermis - 
fkb-6 F31D4.3 (V) D Y Emb/Wt Neuronal B. malayi fkb59; Schistosoma mansoni p50  
fkb-7 B0511.1 (I) D Y Wt Neuronal - 
fkb-8 Y18D10A.25 (I) A N Wt Gut -  
 3 
Information based on C. elegans Wormbase version 145.  Expression patterns are from Page, A.P. (unpublished data).  4 
Phenotypes: Wt = wild-type; Emb = embryonic lethal. Y=yes; N=no. 5 
Fig. 1 
 
TbCYP19         ------------------------------------MSYRPHHATVPTNPKVYFDVSIAG 24 
TcCYP19         ------------------------------------MSYKPHHATVPTNPKVFFDVSIGG 24 
LmCYP19         ------------------------------------MPYTPHYPVVESNPKVWMDIDIGG 24 
hCYP18          -----------------------------------------------VNPTVFFDIAVDG 13 
PfCYP19A        ---------------------------------------------MSKRSKVFFDISIDN 15 
PbCYP19A        ---------------------------------------------MS-RAKVFFDISIDN 14 
TgCYP20         AVFVPITVG-------AVRYTKHPTRLRPGSLPCVAFCLYSSRLSTMPNPRVFFDISIDK 189 
TgCYP18         ---------------------------MKLVLFFLALAVSGAVAENAGVRKAYMDIDIDG 33 
NcCYP           ---------------------------MKLLFFFLVLAVSAAVAENAGVQKAFMDIEIDG 33 
PfCYP19B        ---------------------MNKLVSIILVIFFLFHKYALCAEEHEITHKTYFDITIDD 39 
LdCYP           -----------------------MRFVAVLAVVLCALSFLNVAAEPEVTAKVYFDVMIDS 37 
GiCYP           ---------------------------------MCAQP--RITAAEFVSDKVFFDITIGG 25 
TgFCBP57        VRAKEKSAFGNIFKKVDLYTGKSALLSSSSSSVVSVRAEKQGVRNVSKCPKVYMDIKVGD 360 
EhCYP           ----------------------------------------------MARPKVFFDITIGG 14 
PfCYP24         --MKNLNQNMKNNDNKKNEKISGLEENEEHNNNNIVPYYLSNLLTNPSNPVVFMDINLGN 58 
 
 
                                                               *  # ** *     
TbCYP19         QAAGRITFELFADAVPKTAENFRALCTGEK-------GFGYAGSGFHRIIPQFMCQGGDF 77 
TcCYP19         QSAGRVVFELFADAVPKTAENFRALCTGEK-------NFGYAGSGFHRIIPQFMCQGGDF 77 
LmCYP19         KPAGRVTMELFKDAVPQTAENFRALCTGEK-------GFGYANSPFHRVIPDFMCQGGDF 77 
hCYP18          EPLGRVSFELFADKVPKTAENFRALSTGEK-------GFGYKGSCFHRIIPGFMCQGGDF 66 
PfCYP19A        SNAGRIIFELFSDITPRTCENFRALCTGEK-IGSRGKNLHYKNSIFHRIIPQFMCQGGDI 74 
PbCYP19A        KNAGRIVFELFNDITPRTCENFKSLCIGDK-VGSRGKNLHYKNSIFHRIIPQFMCQGGDI 73 
TgCYP20         KPAGRIEFELFADVVPKTAENFRALCTGEKGTGRSGKPLYYKGCPFHRIIPQFMCQGGDF 249 
TgCYP18         EHAGRIILELREDIAPKTVKNFIGLFD------------KYKGSVFHRIIPDFMIQGGDF 81 
NcCYP           ESAGRIVLELRGDVVPKTVKNFIGLFD------------KYKGSTFHRVIADFMIQGGDF 81 
PfCYP19B        KPLGRIVFGLYGKVAPKTVENFVSICKGTV---VDGKMLHYTNSIFHRIIPNFMAQGGDI 96 
LdCYP           EPLGRITIGLFGKDAPLTTENFRQLCTGEHGFG-------YKDSIFHRVIQNFMIQGGDF 90 
GiCYP           KLFGRITMGLFGSIVPKTAENFKKLCTGEMGFG-------YKGSTFHRVIPKFMIQGGDF 78 
TgFCBP57        NAPKRVVFALYNDTVPKTAENFRALCTGEKGEGKKGKPLCFKNSLFHRVIPGFMMQGGDF 420 
EhCYP           EKAGRIVMELFNDIVPKTAENFRCLCTGEKGNG-----LTYKGCGFHRVIKDFMIQGGDF 69 
Figure 1
PfCYP24         HFLGKFKFELFQNIVPRTSENFRKFCTGEHKIN--NLPVGYKNTTFHRVIKDFMIQGGDF 116 
 
                                                      #                 # 
                 # #*#      ###                     ***#      * *       **   
TbCYP19         TRHNGTGGKSIYGEKFPDESFAGKAGKHFGAGTLSMANAGPNTNGSQFFICTAPTQWLDG 137 
TcCYP19         TNHNGTGGRSIYGEKFADESFAGKAGKHFGLGTLSMANAGPNTNGSQFFICTAPTQWLDG 137 
LmCYP19         TNGNGTGGKSIYGSKFADESFLGKAGKHFGPGTLSMANAGPNTNGSQFFLCTAPTSWLDG 137 
hCYP18          TRHNGTGGKSIYGEKFEDENFI---LKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDG 123 
PfCYP19A        TNGNGSGGESIYGRSFTDENFN---MKHDQPGLLSMANAGPNTNSSQFFITLVPCPWLDG 131 
PbCYP19A        TNGNGSGGESIYGRSFTDENFK---MKHDTPGLLSMANAGPNTNSSQFFITLVPCPWLDG 130 
TgCYP20         TRMNGTGGESIYGEKFADENFS---YKHSEPFLLSMANAGPNTNGSQFFITTVPCPWLDG 306 
TgCYP18         ENHNGTGGHSIYGRRFDDENFD---LKH-ERGVISMANAGPNTNGSQFFITTVKTEWLDA 137 
NcCYP           ENHNGTGGHSIYGPRFEDENFT---LKH-DRGVISMANAGPNTNGSQFFITTVKTEWLDG 137 
PfCYP19B        TNFNGTGGLSIYGKKFEDENFK---VNHSKRGLLSMANAGKNTNGSQFFILFIPTPWLDG 153 
LdCYP           TNFDGTGGKSIYGEKFADENLN---VKHF-VGALSMANAGPNTNGSQFFITTAPTPWLDG 146 
GiCYP           TNHNGTGGKSIYGAKFPDENFE---IKHF-VGSLSMANAGPNTNGSQFFLTVADTAWLDG 134 
TgFCBP57        TNGDGTGGESIYGPQFNDEKFV---DQHTGRGQLSMANCGPNTNSSQFFITFGPAPHLDG 477 
EhCYP           TRHNGTGGKSIYGTKFADEAFT---VKHTKPGMLSMANAGPNTNGSQFFITTVPCPWLDG 126 
PfCYP24         VNYNGSGCISIYGEHFDDENFD---IKHDKEGLLSMANTGPNTNGCQFFIITKKCEWLDG 173 
 
 
                 *                      ##  # 
TbCYP19         KHVVFGQVL--EGMDVVKAMEAVGSQ--GGSTSKPVKIDSCGQL-- 177 
TcCYP19         KHVVFGQVL--EGIEVVKAMEAVGSQ--TGKTSKPVKIEASGQL-- 177 
LmCYP19         KHVVFGQVL--EGYEVVKAMEAVGSR--SGTTSKPVRVSACGQL-- 177 
hCYP18          KHVVFGKVK--EGMNIVEAMERFGSR--NGKTSKKITIADCGQLE- 164 
PfCYP19A        KHVVFGKVI--EGMNVVREMEKEGAK--SGYVKRSVVITDCGEL-- 171 
PbCYP19A        KHVVFGKVI--EGMNVVRDMEKEGSN--SGYVKRPVVITNCGEL-- 170 
TgCYP20         KHVVFGKVV--AGQEVVKMMEAEGRS--NGQPKCAVEISSCGQLS- 347 
TgCYP18         RHVVFGKITT-ESWPTVQAIEALGGS--GGRPSKVAKITDIGLLE- 179 
NcCYP           RHVVFGKITN-DSWPTVQAIEALGSS--GGRPSKIAKITDIGLL-- 178 
PfCYP19B        RHVVFGEVV--EGLDKLVHIEAVGTD--SGEPLKRVLVKESGELPL 195 
LdCYP           RHVVFGKVL--DGMDVVLRIEKTKTN-SHDRPVKPVKIVASGEL-- 187 
GiCYP           KHVVFGRVL--DGMDVVKAIETTKTG-ANDKPVEKVVIADCGVLQ- 176 
TgFCBP57        KHVVFGEVV--EGQDVLDEVEDVETDKSNDRPKQDVQIVDCGEVKC 521 
EhCYP           KHVVFGQVV--EGYDVVKMIENNPTG-AQDKPKKAVVIADCGQL-- 167 
PfCYP24         KNVVFGRIIDNDSLILLKKIENVSVTPYIYKPKIAINIVECGEL-- 217 
Figure 2




17 126 144 177 194 261 304 
hFKBP36 
(O75344) 
37 143 171 204 219 286 327 
TgFCBP57 
(AAX51680) 
487 521 45 150 168 201 217 284 350 
hFKBP37 
(NP_003968) 





323 41 148 167 200 218 285 
hFKBP52 
(Q02790) 
386 406 459 319 420 41 138 149 303 254 270 
hFKBP51 
(U71321) 










Replies to Editor-in Chief’s comments 
 
p12. The reference is correct. The sequence of the S. mansoni cyp-13 orthologue is 
depicted in Valle et al., 2005.  The accession number goes back to another reference 
(Davis,R.E., Hardwick,C., Tavernier,P., Hodgson,S., Singh,H., 1995. RNA trans-splicing 
in flatworms. Analysis of trans-spliced mRNAs and genes in the human parasite, 
Schistosoma mansoni. J. Biol. Chem. 270 (37), 21813-21819) but in this article the 
sequence was not shown. 
 
p 12 and 21-22: We agree that this modification was perhaps too vague.  We have 
defined our points more precisely now (p 12 21-25; p21 line 22 – p 22 line 6). 
 
p 22: We have replaced the reference to the Sanger web-site with the relevant literature 
citations. 
 
p 39: The Nunes (p 7 line 16; p 13 line 6; Table 1) and Monaghan (p 25 line 21) theses 
have been cited fully in the text and removed from the references. 
 
All other corrections have been made as requested. 
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